KOPS - The Institutional Repository of the University of Konstanz

Efficacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis

Efficacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis

Cite This

Files in this item

Checksum: MD5:09be7c13d917386b4621f4c75c7b5484

SINKEVICIUTE, Igne, Marieke BEGEMANN, Merel PRIKKEN, Bob ORANJE, Erik JOHNSEN, Wan U. LEI, Kenneth HUGDAHL, Rune A. KROKEN, Carina RAU, Jolien D. JACOBS, 2018. Efficacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis. In: npj Schizophrenia. 4(1), 22. eISSN 2334-265X. Available under: doi: 10.1038/s41537-018-0064-6

@article{Sinkeviciute2018-10-25Effic-45431, title={Efficacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis}, year={2018}, doi={10.1038/s41537-018-0064-6}, number={1}, volume={4}, journal={npj Schizophrenia}, author={Sinkeviciute, Igne and Begemann, Marieke and Prikken, Merel and Oranje, Bob and Johnsen, Erik and Lei, Wan U. and Hugdahl, Kenneth and Kroken, Rune A. and Rau, Carina and Jacobs, Jolien D.}, note={Article Number: 22} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/45431"> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/45431"/> <dc:contributor>Johnsen, Erik</dc:contributor> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/45431/1/Sinkeviciute_2-1sccnthe7udev5.pdf"/> <dc:contributor>Sinkeviciute, Igne</dc:contributor> <dcterms:title>Efficacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis</dcterms:title> <dc:language>eng</dc:language> <dc:contributor>Rau, Carina</dc:contributor> <dc:creator>Kroken, Rune A.</dc:creator> <dc:contributor>Hugdahl, Kenneth</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <dc:creator>Rau, Carina</dc:creator> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Sinkeviciute, Igne</dc:creator> <dcterms:abstract xml:lang="eng">Cognitive impairment is a core feature of schizophrenia, which is predictive for functional outcomes and is, therefore, a treatment target in itself. Yet, literature on efficacy of different pharmaco-therapeutic options is inconsistent. This quantitative review provides an overview of studies that investigated potential cognitive enhancers in schizophrenia. We included pharmacological agents, which target different neurotransmitter systems and evaluated their efficacy on overall cognitive functioning and seven separate cognitive domains. In total, 93 studies with 5630 patients were included. Cognitive enhancers, when combined across all different neurotransmitter systems, which act on a large number of different mechanisms, showed a significant (yet small) positive effect size of 0.10 (k = 51, p = 0.023; 95% CI = 0.01 to 0.18) on overall cognition. Cognitive enhancers were not superior to placebo for separate cognitive domains. When analyzing each neurotransmitter system separately, agents acting predominantly on the glutamatergic system showed a small significant effect on overall cognition (k = 29, Hedges' g = 0.19, p = 0.01), as well as on working memory (k = 20, Hedges' g = 0.13, p = 0.04). A sub-analysis of cholinesterase inhibitors (ChEI) showed a small effect on working memory (k = 6, Hedges' g = 0.26, p = 0.03). Other sub-analyses were positively nonsignificant, which may partly be due to the low number of studies we could include per neurotransmitter system. Overall, this meta-analysis showed few favorable effects of cognitive enhancers for patients with schizophrenia, partly due to lack of power. There is a lack of studies involving agents acting on other than glutamatergic and cholinergic systems, especially of those targeting the dopaminergic system.</dcterms:abstract> <dc:creator>Jacobs, Jolien D.</dc:creator> <dc:contributor>Begemann, Marieke</dc:contributor> <dc:contributor>Oranje, Bob</dc:contributor> <dc:creator>Begemann, Marieke</dc:creator> <dc:creator>Lei, Wan U.</dc:creator> <dc:creator>Johnsen, Erik</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <dc:contributor>Kroken, Rune A.</dc:contributor> <dc:contributor>Prikken, Merel</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-03-12T16:14:43Z</dc:date> <dc:rights>Attribution 4.0 International</dc:rights> <dc:creator>Hugdahl, Kenneth</dc:creator> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/> <dc:creator>Prikken, Merel</dc:creator> <dcterms:issued>2018-10-25</dcterms:issued> <dc:creator>Oranje, Bob</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-03-12T16:14:43Z</dcterms:available> <dc:contributor>Jacobs, Jolien D.</dc:contributor> <dc:contributor>Lei, Wan U.</dc:contributor> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/45431/1/Sinkeviciute_2-1sccnthe7udev5.pdf"/> </rdf:Description> </rdf:RDF>

Downloads since Mar 12, 2019 (Information about access statistics)

Sinkeviciute_2-1sccnthe7udev5.pdf 147

This item appears in the following Collection(s)

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International

Search KOPS


My Account